Phase II study of alemtuzumab in chronic lymphoproliferative disorders

Alessandra Ferrajoli*, Susan M. O'Brien, Jorge E. Cortes, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Razelle Kurzrock, Susan Lerner, Dimitrios P. Kontoyiannis, Michael J. Keating

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

122 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of alemtuzumab in chronic lymphoproliferative disorders'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science